SCHEMBL21530470

SCHEMBL21530470

Cc1ccc(Nc2nc(N)nc(CN3CCN(Cc4ccc5c(c4)OCO5)CC3)n2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 1.00
USP2 O75604 7/20 1.00
LMNA P02545 6/20 1.00
MAPK1 P28482 4/20 1.00
ALOX15 P16050 1/20 1.00
MEN1 O00255 1/20 0.82
KMT2A Q03164 1/20 0.82
NPSR1 Q6W5P4 2/20 0.81
SMN1; SMN2 Q16637 3/20 0.78
ATM Q13315 2/20 0.67
GAA P10253 2/20 0.66
MAPT P10636 3/20 0.64
L3MBTL1 Q9Y468 2/20 0.64
NPC1 O15118 1/20 0.63
RAB9A P51151 1/20 0.63
HTT P42858 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
CYBB P04839 1/20 0.58
NOX5 Q96PH1 1/20 0.58
NOX3 Q9HBY0 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21530421 0.80 SMN1; SMN2 (1.00) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL21530407 0.79 MAPK1 (0.78) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL15662302 0.76 MAPT (0.80) ALDH1A1USP2LMNAMAPK1MEN1
SCHEMBL17999762 0.73 CYBB (1.00) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL30100838 0.73 CYBB (1.00) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL21530475 0.72 MAPT (0.85) ALDH1A1USP2LMNAMAPK1MEN1
SCHEMBL26317575 0.72 SMN1; SMN2 (0.72) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL108678 0.71 KDM4E (0.70) USP2MAPK1MEN1KMT2A
SCHEMBL17100737 0.71 ALDH1A1 (0.55) ALDH1A1USP2LMNAMAPK1ALOX15
SCHEMBL14869453 0.70 LMNA (0.62) ALDH1A1USP2LMNAMAPK1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-11739072-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2023-08-29 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2022-05-05 US disclosed
EP-3562811-B1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S L (ES) 2022-03-16 EP disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-11174242-B2 Heteroaryl compounds and their use MINORYX THERAPEUTICS S.L. (ES) 2021-11-16 US disclosed
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE MINORYX THERAPEUTICS S.L. (ES) 2019-11-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220135535-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA ALDH1A1 1097/4885USP2 2529/4885LMNA 127/4885
US-20190337922-A1 HETEROARYL COMPOUNDS AND THEIR USE GBA1, GBA2, GAA ALDH1A1 1097/4885USP2 2529/4885LMNA 127/4885
US-11174242-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA ALDH1A1 1097/4885USP2 2529/4885LMNA 127/4885
US-11739072-B2 Heteroaryl compounds and their use GBA1, GBA2, GAA ALDH1A1 1097/4885USP2 2529/4885LMNA 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.